Transient Neonatal Diabetes Mellitus (TNDM) Cell Models for Research

Transient Neonatal Diabetes Mellitus (TNDM) is a rare form of diabetes that occurs within the first six months of life, with an estimated incidence of 1 in 90,000 to 1 in 260,000 live births (WHO, 2023). It is characterized by hyperglycemia that typically resolves within the first 18 months, but affected individuals often develop diabetes later in life. The condition is associated with genetic abnormalities affecting pancreatic beta-cell development and function. Key risk factors include mutations in imprinted genes on chromosome 6q24, as well as mutations in genes such as KCNJ11 and ABCC8. The clinical impact is significant due to the potential for neurological complications and long-term metabolic consequences. Research on TNDM is crucial for understanding beta-cell biology and developing targeted therapies.

TNDM serves as an excellent model for studying beta-cell function and insulin secretion. Its well-defined genetic causes allow for precise modeling of specific mutations. The disease has distinct subtypes, including those caused by 6q24 abnormalities and those due to KCNJ11/ABCC8 mutations, providing opportunities to study different molecular mechanisms. Public datasets, such as those from the NCBI Gene and ClinVar, offer extensive genetic information. Open questions include the molecular basis of remission and relapse, and the long-term effects of early metabolic disturbances. Gene-edited cell models are invaluable for dissecting these mechanisms and testing potential therapies.

While TNDM is not a cancer, the underlying pathways are critical for beta-cell function. The major pathways include:

• • Insulin secretion pathway: Involves glucose sensing, ATP production, and KATP channel closure.
• • Pancreatic development pathway: Transcription factors such as PDX1, NEUROG3, and PAX6 regulate beta-cell differentiation.
• • Imprinting pathway: Abnormal methylation at 6q24 leads to overexpression of PLAGL1 and HYMAI, affecting beta-cell function.

These pathways are disrupted in TNDM, leading to insufficient insulin secretion.

Data from NCBI Gene, ClinVar, and COSMIC.

Key signaling networks affected in TNDM:

• • KATP channel signaling: Mutations in KCNJ11 and ABCC8 alter channel function, affecting insulin secretion.
• • Glucose sensing pathway: Impaired glucose uptake and metabolism due to beta-cell dysfunction.
• • Transcriptional networks: Impaired expression of key transcription factors (PDX1, NEUROG3) due to imprinting defects.

These networks are interconnected and critical for maintaining glucose homeostasis.

Organoids derived from human pluripotent stem cells (hPSCs) can be generated to model TNDM mutations, providing a more physiologically relevant system.

• • Patient-derived xenografts (PDX): Not commonly used for TNDM due to the non-cancerous nature.
• • Genetically engineered mouse models (GEMM): Knock-in mice with KCNJ11 mutations (e.g., V59M) recapitulate TNDM features.
• • Induced models: Chemical induction of diabetes in mice (e.g., streptozotocin) can be used for beta-cell studies.

These models help study disease mechanisms and test therapeutic interventions.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific TNDM mutations. For example:

• • KCNJ11 knockout cell lines: Generated by introducing frameshift mutations, leading to loss of function.
• • ABCC8 point-mutation knock-in lines: Mimic patient-specific mutations (e.g., R1353H) to study their impact.
• • INS reporter lines: Tagged with fluorescent proteins to monitor insulin expression.

These models are commercially available, sequence-verified, and can be used for drug screening and functional studies. They offer a controlled system to dissect the effects of specific mutations.

Gene-edited cell lines are used to validate the function of genes implicated in TNDM. For example:

• • KCNJ11 knockout lines confirm the role of the KATP channel in insulin secretion.
• • ABCC8 mutant lines demonstrate the impact of specific mutations on channel function.

These models allow researchers to study gene function in a controlled environment.

Isogenic pairs (wild-type vs. mutant) are used for high-throughput drug screening. For instance:

• • Screening for compounds that enhance insulin secretion in KCNJ11 mutant lines.
• • Testing drugs that modulate KATP channel activity.

These screens can identify potential therapies for TNDM and related conditions.

CRISPR-based synthetic lethality screens can identify genes that are essential for survival of cells with specific TNDM mutations. This can lead to the discovery of novel biomarkers and therapeutic targets.